Cargando…
Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa
Background. Pain is one of the main aspects of hidradenitis suppurativa that strongly affects the quality of life of patients. We explored the relationship between pain and clinical severity as well as its role in defining the health status in patients with HS. Methods. Pain was defined by three mea...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397122/ https://www.ncbi.nlm.nih.gov/pubmed/34441944 http://dx.doi.org/10.3390/jcm10163648 |
_version_ | 1783744543577866240 |
---|---|
author | Sampogna, Francesca Campana, Irene Fania, Luca Mastroeni, Simona Fusari, Roberta Ciccone, Davide Pallotta, Sabatino Abeni, Damiano |
author_facet | Sampogna, Francesca Campana, Irene Fania, Luca Mastroeni, Simona Fusari, Roberta Ciccone, Davide Pallotta, Sabatino Abeni, Damiano |
author_sort | Sampogna, Francesca |
collection | PubMed |
description | Background. Pain is one of the main aspects of hidradenitis suppurativa that strongly affects the quality of life of patients. We explored the relationship between pain and clinical severity as well as its role in defining the health status in patients with HS. Methods. Pain was defined by three measures: (a) question 1 (“my skin hurts”) of the Skindex-17; (b) Bodily Pain (BP) scale of the SF-36; and (c) Visual Analog Scale (VAS). Clinical severity of HS was assessed by the Hurley staging, the Sartorius HS Score, and the International HS Severity Score System. Results. The study population included 341 HS patients with complete data for the VAS pain, 316 for question 1 of the Skindex-17, and 294 for BP. Clinical severity was positively associated with pain. This result was observed for all three severity scores and all three pain evaluation methods. In addition, the number of fistulae, abscesses, and nodules were significantly associated with the three severity measures of pain, while the association with scars was not observed for question 1 of the Skindex-17 and BP. Conclusions. Pain may be a good proxy of clinical severity and efficacy of a treatment in HS and therefore a crucial hallmark of patients’ health status. |
format | Online Article Text |
id | pubmed-8397122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83971222021-08-28 Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa Sampogna, Francesca Campana, Irene Fania, Luca Mastroeni, Simona Fusari, Roberta Ciccone, Davide Pallotta, Sabatino Abeni, Damiano J Clin Med Article Background. Pain is one of the main aspects of hidradenitis suppurativa that strongly affects the quality of life of patients. We explored the relationship between pain and clinical severity as well as its role in defining the health status in patients with HS. Methods. Pain was defined by three measures: (a) question 1 (“my skin hurts”) of the Skindex-17; (b) Bodily Pain (BP) scale of the SF-36; and (c) Visual Analog Scale (VAS). Clinical severity of HS was assessed by the Hurley staging, the Sartorius HS Score, and the International HS Severity Score System. Results. The study population included 341 HS patients with complete data for the VAS pain, 316 for question 1 of the Skindex-17, and 294 for BP. Clinical severity was positively associated with pain. This result was observed for all three severity scores and all three pain evaluation methods. In addition, the number of fistulae, abscesses, and nodules were significantly associated with the three severity measures of pain, while the association with scars was not observed for question 1 of the Skindex-17 and BP. Conclusions. Pain may be a good proxy of clinical severity and efficacy of a treatment in HS and therefore a crucial hallmark of patients’ health status. MDPI 2021-08-18 /pmc/articles/PMC8397122/ /pubmed/34441944 http://dx.doi.org/10.3390/jcm10163648 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sampogna, Francesca Campana, Irene Fania, Luca Mastroeni, Simona Fusari, Roberta Ciccone, Davide Pallotta, Sabatino Abeni, Damiano Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa |
title | Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa |
title_full | Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa |
title_fullStr | Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa |
title_full_unstemmed | Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa |
title_short | Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa |
title_sort | pain as defining feature of health status and prominent therapeutic target in patients with hidradenitis suppurativa |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397122/ https://www.ncbi.nlm.nih.gov/pubmed/34441944 http://dx.doi.org/10.3390/jcm10163648 |
work_keys_str_mv | AT sampognafrancesca painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa AT campanairene painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa AT fanialuca painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa AT mastroenisimona painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa AT fusariroberta painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa AT cicconedavide painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa AT pallottasabatino painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa AT abenidamiano painasdefiningfeatureofhealthstatusandprominenttherapeutictargetinpatientswithhidradenitissuppurativa |